NEW YORK – Saladax Biomedical announced on Tuesday that it has acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica.
The portfolio covers 17 patent families and has resulted in 33 US patents and 296 patents outside of the US, the firm said in a statement. This intellectual property, in combination with Saladax's current IP, covers the major antipsychotic drugs covered worldwide, Saladax added.
Bethlehem, Pennsylvania-based Saladax currently offers antipsychotic drug tests for clinical chemistry analyzers, as well as a point-of-care platform for use in places where centralized labs may not be available. Its rapid test to measure levels of clozapine, a drug used to treat schizophrenia, received de novo clearance from the US Food and Drug Administration in 2020.
Last month, Saladax announced a deal with Danaher subsidiary Beckman Coulter to globally distribute Saladax's MyCare Psychiatry Laboratory Assays.